Low density lipoprotein cholesterol, statins and cardiovascular events: a meta-analysis
The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.
Abstract
A recent meta-analysis of the Cholesterol Treatment Trialists' (CTT) Collaboration comes to the clear conclusion that a reduction in LDL-C using statins of 1 mmol/l (39 mg/dl) leads to a decrease in overall mortality by 12%, in coronary mortality by 19% and in the incidence of strokes by 17%, independent of the LDL-C level prior to the start of treatment. We conducted a systematic review retrieving 18 studies with a total of 116,343 [corrected] participants. Differences in average LDL-C reductions between the intervention and control groups during the follow-up and relative risks according to different clinical endpoints were extracted from the original publications. Metaregression analyses showed that reduction in LDL-C accounted for more than 75% of the variance in risk reductions for overall mortality and cardiovascular endpoints. On the basis of our estimates, a reduction in LDL-C of 1 mmol/l (39 mg/dl) leads to reductions in overall mortality, coronary mortality, incidence of non-fatal myocardial infarction, the combination of coronary mortality and non-fatal myocardial infarction, stroke and any vascular event by 15% (95% CI: 11-20%), 24% (95% CI: 20-28%), 27% (95% CI: 20-32%), 25% (95% CI: 22-29%), 24% (18-29%) and 22% (95% CI: 19-26%), respectively. We conclude that the extent to which statins lower LDL-C is strongly related to the improvement of clinical outcomes achieved by this class of drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The comparative evaluation of berberine and lifestyle intervention or placebo indicated that in the berberine group, LDL-C and plasma TG levels were more effectively reduced than in the control group.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [191]
Citations
Cites
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236 · cited 1×
“Due to an unexplained and thus apparently arbitrary limitation to studies of patients with stable coronary heart disease, acute coronary syndrome or studies in which diabetics were a predefined subgroup, the studies WOSCOPS [31], AFCAPS/TeXCAPS [6], ALLHAT-LLT [27] and ALERT [10] were not taken into consideration by t…”
ResultIntensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755 · cited 1×
“For three of the 12 studies (ASCOT [23], CARDS [4] and MIRACL [21]), we were not able to follow the “difference in relative decrease in LDL-C” on the basis of the original publications.”
Background
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Tabas, I., Williams, K. J., & Borén, J. (2007) · Circulation · doi:10.1161/circulationaha.106.676890 · Cited by 1,399
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Lipid lowering with PCSK9 inhibitors
Dadu, R. T., & Ballantyne, C. M. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.84 · Cited by 237
Epidemiology and prevention of stroke: a worldwide perspective
Kuklina, E. V., Tong, X., George, M. G., & Bansil, P. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.99 · Cited by 177
“However, evidence indicates that low LDL-C levels achieved during intensive statin treatment, are not significantly associated with an increased risk for hemorrhagic stroke, except in patients with a history of intracerebral hemorrhagic stroke [22,23].”
Vitale, M., Masulli, M., Calabrese, I., Rivellese, A., Bonora, E., Signorini, S., Perriello, G., Squatrito, S., Buzzetti, R., Sartore, G., et al. (2018) · Nutrients · doi:10.3390/nu10081067 · Cited by 152
März, W., Genser, B., Drechsler, C., Krane, V., Grammer, T. B., Ritz, E., Stojakovic, T., Scharnagl, H., Winkler, K., Holme, I., et al. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09121010 · Cited by 145
“Meta-analyses of prospective trials of statins have revealed an approximately 25% reduction in cardiovascular events per 39-mg/dl (1 mmol/L) decrease in LDL-C (4,16,17).”
BackgroundSelf-citationEstablished and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109
PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future
Shimada, Y. J., & Cannon, C. P. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv174 · Cited by 98
de Rougemont, A., Normand, S., Nazare, J.-A., Skilton, M. R., Sothier, M., Vinoy, S., & Laville, M. (2007) · British Journal of Nutrition · doi:10.1017/s0007114507778674 · Cited by 81
Huijgen, R., Abbink, E. J., Bruckert, E., Stalenhoef, A. F. H., Imholz, B. P. M., Durrington, P. N., Trip, M. D., Eriksson, M., Visseren, F. L. J., Schaefer, J. R., et al. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.04.014 · Cited by 80
Lipid Paradox in Acute Myocardial Infarction—The Association With 30-Day In-Hospital Mortality
Cheng, K., Chu, C., Lin, T., Lee, K., Sheu, S., & Lai, W. (2015) · Critical Care Medicine · doi:10.1097/ccm.0000000000000946 · Cited by 80
Vitale, M., Vaccaro, O., Masulli, M., Bonora, E., Prato, S. D., Giorda, C. B., Nicolucci, A., Squatrito, S., Auciello, S., Babini, A. C., et al. (2016) · Clinical Nutrition · doi:10.1016/j.clnu.2016.11.002 · Cited by 87
PCSK9: Regulation and Target for Drug Development for Dyslipidemia
Burke, A. C., Dron, J. S., Hegele, R. A., & Huff, M. W. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104944 · Cited by 74
Stacy, J. N., Schwartz, S. M., Ershoff, D., & Shreve, M. S. (2009) · Population Health Management · doi:10.1089/pop.2008.0046 · Cited by 63
Laufs, U., Karmann, B., & Pittrow, D. (2016) · Clinical Research in Cardiology · doi:10.1007/s00392-016-0991-z · Cited by 59
“Lipid abnormalities are highly prevalent under clinical practice conditions [6, 9, 10, 12, 37].”
BackgroundSimvastatin: Two Decades in a Circle
Kolovou, G. D., Vasiliadis, I. K., Anagnostopoulou, K., & Cokkinos, D. V. (2008) · Cardiovascular Therapeutics · doi:10.1111/j.1527-3466.2008.00047.x · Cited by 53
“Until recently, it was believed that the beneficial effect of statins was due solely to their lipid-lowering actions (Ballantyne 2005; Cheng and Leiter 2006; Genser and Marz 2006; Steinberg 2006).”
BackgroundLee, C., Park, J. T., Chang, T. I., Kang, E. W., Nam, K. H., Joo, Y. S., Sung, S. A., Kim, Y. H., Chae, D., Park, S. K., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.09.037 · Cited by 46
26 Years of LDL – Apheresis: A review of experience
Borberg, H. (2009) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2009.05.013 · Cited by 40
Ziaei, R., Ghavami, A., Khalesi, S., Ghiasvand, R., & Mokari‐Yamchi, A. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.12.023 · Cited by 41
Lu, Y., Cheng, Z., Zhao, Y., Chang, X., Chan, C., Bai, Y., & Cheng, N. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.10.025 · Cited by 44
Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives
He, N.-Y., Li, Q., Wu, C., Ren, Z., Gao, Y., Pan, L.-H., Wang, M., Wen, H.-Y., Jiang, Z., Tang, Z., et al. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.134 · Cited by 38
Rozner, S., Kogan, A., Mehta, S. C., Somasundaran, P., Aserin, A., Garti, N., & Ottaviani, M. F. (2008) · The Journal of Physical Chemistry B · doi:10.1021/jp807163t · Cited by 31
Gu, L., Wang, Y., Xu, Y., Tian, Q., Lei, G., Zhao, C., Gao, Z., Pan, Q., Zhao, W., Nong, L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20590 · Cited by 29
“Over the past decades, the use of statins to reduce LDL-C has successfully decreased the risk of cardiovascular events [44, 45], successfully in treating dyslipidemia as a major means for diminishing”
BackgroundHarley, C., Gandhi, S. K., Heien, H. C., McDonough, K., & Nelson, S. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.5.669 · Cited by 25
“Clinical data have demonstrated the effectiveness of reducing LDL-C levels, increasing HDL cholesterol (HDL-C) levels and decreasing triglycerides in diabetes patients to reduce the risk of significant coronary events, including death [15-18] .”
BackgroundLDL-Cholesterol: Standards of Treatment 2016: A German Perspective
März, W., Scharnagl, H., Gouni‐Berthold, I., Silbernagel, G., Dressel, A., Grammer, T. B., Landmesser, U., Dieplinger, H., Windler, E., & Laufs, U. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0179-y · Cited by 22
Self-citationForzano, I., Florimonte, D., Narciso, V., Canonico, M. E., Castiello, D. S., Manzi, L., Cristiano, S., Spinelli, A. M., Vallone, D. M., D’Alconzo, D., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14238334 · Cited by 18
“The benefits of statins in reducing CV risk is mainly driven by lowering plasma LDL-C levels [77–79].”
Yang, X., So, W. Y., Ma, R., Ko, G., Kong, A. P. S., Lam, C. C. F., Ho, C. S., Cockram, C. S., Chow, C. C., Tong, P. C. Y., et al. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn149 · Cited by 17
Laufs, U., NEF, H. M., Möllmann, H., Custodis, F., & Böhm, M. (2007) · Clinical Research in Cardiology · doi:10.1007/s00392-008-0625-1 · Cited by 14
Trends in age-standardised and age-specific mortality from ischaemic heart disease in Germany
Müller‐Riemenschneider, F., Andersohn, F., & Willich, S. N. (2010) · Clinical Research in Cardiology · doi:10.1007/s00392-010-0151-9 · Cited by 13
Regional variation of mortality from ischemic heart disease in Germany from 1998 to 2007
Andersohn, F., Schlattmann, P., Roll, S., Müller‐Riemenschneider, F., Binting, S., & Willich, S. N. (2010) · Clinical Research in Cardiology · doi:10.1007/s00392-010-0150-x · Cited by 12
“vascular risk factors such as smoking, obesity [7, 8], physical inactivity, hypertension, hyperlipidemia [9], diabetes [10], etc.”
BackgroundCell signaling and biological pathway in cardiovascular diseases
Chae, C.-W., & Kwon, Y. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01141-0 · Cited by 14
First Iranian guidelines for the diagnosis, management, and treatment of hyperlipidemia in adults
Bagherikholenjani, F., Shahidi, S., Vaseghi, G., Ashoorion, V., Sarrafzadegan, N., Siavash, M., Heidarpour, M., Shahidi, S., Sadeghi, M., Mohammadifard, N., et al. (2024) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_318_23 · Cited by 12
A Jordanian Multidisciplinary Consensus Statement on the Management of Dyslipidemia
Mousa, E. A., Al-Azzam, S. I., Araydah, M., Karasneh, R. A., Ghnaimat, M. A., Al-Makhamreh, H. K., Khawaldeh, A., Al-Samen, M. A. A., HADDAD, J. A., Najjar, S. A., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134312 · Cited by 9
Möllmann, H., NEF, H. M., Böhm, M., & Laufs, U. (2008) · Clinical Research in Cardiology · doi:10.1007/s00392-008-0742-x · Cited by 11
The case for statin therapy in chronic heart failure
van der Harst, P., Böhm, M., van Gilst, W. H., & van Veldhuisen, D. J. (2007) · Clinical Research in Cardiology · doi:10.1007/s00392-007-0610-0 · Cited by 7
“Although hypercholesterolemia is a well-established risk factor for the development of CAD and treating cholesterol levels in CAD is beneficial [10], this is not necessarily the case for CHF.”
Cardiovascular risk reduction in referrals to outpatient vascular clinics
Stather, P., Muscara, F., Benson, R. A., Blackwell, J., Bootun, R., Bosanquet, D. C., Brooke, P., Busuttil, A., Coupland, A., Dattani, N., et al. (2017) · Annals of The Royal College of Surgeons of England · doi:10.1308/rcsann.2017.0204 · Cited by 6
“Evidence regarding the use of cholesterol lowering therapy in patients with established cardiovascular disease is well described, with reduction in low density lipoprotein-C by 1mmol/l decreasing overall mortality, coronary mortality and any vascular event by 15%, 24% and 22% respectively.(25) Moreover, high dose stat…”
BackgroundLíška, B., Khattab, A. A., Herrmann, L., Abdel‐Wahab, M., Westphal, R., Tölg, R., Geist, V., & Richardt, G. (2008) · Herz · doi:10.1007/s00059-008-3084-6 · Cited by 5
“Similar data were published from a meta-analysis of 18 statin trials showing 15% reduction in overall mortality, 24% in coronary mortality, 27% reduction of incidence of nonfatal myocardial infarction, and 24% of stroke per 39 mg/dl [13].”
ResultMTD-comsia modelling of HMG-CoA reductase inhibitors
Duda-Seiman, D., Avram, S., Mancaş, S., Careja, V., Duda-Seiman, C., Putz, M. V., & Ciubotariu, D. (2011) · Journal of the Serbian Chemical Society · doi:10.2298/jsc100601019d · Cited by 5
Zhao, Y., Li, W., Li, W., Tao, H., Li, Y., Wu, B., Wang, X., Zhou, H., & Gao, B. (2022) · BioMed Research International · doi:10.1155/2022/9039377 · Cited by 3
“…syndrome [3], among which low-density lipoprotein cholesterol (LDLc) is a type of the lipoprotein; lowering LDLc could decrease the risk of CVD [4, 5], such as stroke, which is the fi fth leading cause of death in 2017 in the United States [6]; atherosclerosis; and myocardial infarction [7, 8].”
Safety and efficacy of alirocumab: A meta analysis of 12 randomized controlled trials
Shukla, A. K., & Mehani, R. (2019) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_406_19 · Cited by 3
“[8] Irrespective of LDL‐C level prior to the commencement of therapy, reduction in LDL‐C with statins of 1 mmol/l (39 mg/dl) have been found to decrease in overall mortality by 12%, in incidence of strokes by 17%, and in coronary mortality by 19%.[9] Data collected from numerous animal, epidemiologic, genetic, and cli…”
Powell, J. P., & Leonard, J. S. (2008) · Journal of Chiropractic Medicine · doi:10.1016/j.jcm.2008.05.002 · Cited by 4
Reichert, R. G., Lyon, M. R., Kacinik, V., Gahler, R. J., Manjoo, P., Purnama, M., & Wood, S. (2013) · Journal of Complementary and Integrative Medicine · doi:10.1515/jcim-2013-0003 · Cited by 3
“The decrease of LDL-C observed in our participants is comparable to the effects seen in those employing statin medications [22].”
BackgroundResultCabezas, M. C., Orsini, M., Tokgözoğlu, L., Marx, N., Tuñón, J., Vrablík, M., Tavori, H., Bhatt, D. L., & Filardi, P. P. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.10.062 · Cited by 2
Precision medicine to change the landscape of cardiovascular drug development
Dubois, A., Dubé, M., & Tardif, J. (2017) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2017.1392826 · Cited by 2
Élévation du cholestérol et/ou des triglycérides
Foubert, L. (2008) · EMC - Traité de médecine AKOS · doi:10.1016/s1634-6939(08)49410-3 · Cited by 2
Differences in Statin Usage and Target-Goal Achievement between Departments at the Same Hospital
Chen, Z., Wang, X., Ding, Z., Fan, P., & Ma, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050466 · Cited by 1
Klose, G., März, W., Grammer, T. B., & Nitschmann, S. (2010) · Der Internist · doi:10.1007/s00108-009-2570-0 · Cited by 1
Self-citationThe year in Clinical Research in Cardiology
Böhm, M., & Katus, H. A. (2009) · Clinical Research in Cardiology · doi:10.1007/s00392-009-0762-1 · Cited by 1
Pfützner, A. H., Forst, T., März, W., & Jacob, S. (2007) · Der Internist · doi:10.1007/s00108-007-1830-0 · Cited by 1
“Die Vorgehensweise des IQWIG ist durchaus bemerkenswert, sodass wir sie zum Gegenstand einer eigenständigen Publikation gemacht haben [16].”
Self-citationShivpuri, S. (2013) · eScholarship (California Digital Library) · Cited by 1
Foubert, L. (2009) · Elsevier eBooks · doi:10.1016/b978-2-294-01781-0.50148-5
März, W. (2007) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Self-citationRecurrent angina after complete coronary revascularization
Möllmann, H., NEF, H. M., Weber, M. W., Rau, M., Dill, T., Hamm, C. W., & Elsässer, A. (2007) · Clinical Research in Cardiology · doi:10.1007/s00392-007-0505-0
Goto, S. (2010) · Circulation Journal · doi:10.1253/circj.cj-10-0176
Innalzamento del colesterolo e/o dei trigliceridi
Foubert, L. (2008) · EMC - AKOS - Trattato di Medicina · doi:10.1016/s1634-7358(08)70367-x
Elevación del colesterol y/o los triglicéridos
Foubert, L. (2008) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(08)70586-5
Beleslin, B., Deljanin, M., Kanjuh, V., Parapid, B. J., Giga, V. L., Prostran, M. S., Angelkov, L., Balinovac, J., Bikicki, M., Ambrosio, G., et al. (2013)
Best practice principles for cholesterol lowering
Weston, C. F. M. (2007) · Edge Hill University Research Information Repository (Edge Hill University)
Catapano, A. L. (2007) · European Cardiology Review · doi:10.15420/ecr.2007.0.1.26
PCSK9 monokloonsed antikehad düslipideemia raviks: evolokumab ja alirokumab
Irs, A. (2015) · Ajakirjad. Journals by UT · doi:10.15157/ea.v0i0.12350
Statins: Are they really all the same?
Cortese, F. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180713120217
Senkung des LDL-Cholesterins: Wie viel ist gut genug?
März, W., & Grammer, T. B. (2007) · Der Internist · doi:10.1007/s00108-007-1810-4 · Cited by 1
“Schließlich zeigen praktisch alle Interventionsstudien, dass eine Absenkung des LDLC unabhängig von der Therapieform die Inzidenzrate kardiovaskulärer Ereignisse senkt, und zwar um so mehr, je stärker das LDL-C vermindert wird [1, 5, 6].”
BackgroundSelf-citationSkeletal Muscle and Cardiovascular Health
Ruiz‐Ramie, J. J., Davis, P. G., Anderson, E., & Durstine, J. L. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-88361-3_26
Modulation de la phase postprandiale du glucose
Nazare, J. (2009) · theses.fr (ABES) · doi:10.70675/6f38336czb0f0z4d7bzb85ez2898e68b8822 · Cited by 5
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention
Michaeli, D. T. (2024) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00035637
Metadata
- Authors
- Genser, B., & März, W.
- Affiliations
- Synlab (Germany) (DE)
- Corresponding author
- März, Winfried
- Venue
- Clinical Research in Cardiology
- Published
- 2006-06-20
- Volume
- 95
- Issue
- 8
- Pages
- 393-404
- ISSN
- 1861-0684 (ISSN-L)
- 1861-0692
- OpenAlex
- W1978218523
- Cited by
- 68
- References
- 35
- Citations by year
- 2025: 3 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 1 · 2020: 1 · 2019: 4 · 2018: 2 · 2017: 4 · 2016: 7 · 2015: 3 · 2014: 1 · 2013: 3 · 2012: 2
- FWCI
- 8.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Clinical Research in Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- LDL cholesterol, statins, LDL cholesterol lowering, cardiovascular events, all-cause mortality, coronary heart disease mortality, myocardial infarction, stroke, vascular events, meta-regression
- MeSH terms
- Cardiovascular Diseases, Humans, Cholesterol, LDL, Prognosis, Risk Factors, Incidence, Survival Rate, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.